nitisinone
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: 4-hydroxyphenylpyruvate dioxygenase.
- Target
- 4-hydroxyphenylpyruvate dioxygenase
- Mechanism
- 4-hydroxyphenylpyruvate dioxygenase inhibitor
pharma · ETON
Eton Pharmaceuticals
Eton Pharmaceuticals drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
DEER PARK, IL, USA HQ
Public company Type
ETON · NYSE Ticker
Company details
- Status
- Public
- HQ
- DEER PARK, IL, USA
- Programs
- 0
- Drugs
- 3
- Patents
- 163
Eton Pharmaceuticals pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Eton Pharmaceuticals drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor antagonist
-
US regulatory status: approved. Mechanism: Blocks absorption of copper and induces the production of the copper-binding protein metallothionein..
- Mechanism
- Blocks absorption of copper and induces the production of the copper-binding protein metallothionein.